Gennova’s fight against the COVID-19 Pandemic
COVID-19 disease is caused by the new coronavirus SARS-COV-2, which is responsible for the outbreak that started in Wuhan, China in December 2019 and since then has become a global pandemic. Coronaviruses infect both humans and animals and are responsible for respiratory infection ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS).
This pandemic has taken a heavy toll on our families & friends, societal structure, jobs, health care systems, economies, supply chains, entertainment & sports, travel, hospitality services, etc. and will continue to adversely impact us all. According to the WHO, the entire world is at risk until the virus threatens any country.
Almost all industrial sectors have been affected – some severely – and a recession or even a depression looms large in the near future. There is an increasing unmet need to combat the detrimental effects of this deadly and infectious virus. Various players across the world are collectively racing against time to find viable solutions.
Unless vaccines and/or drugs can arrest, cure, mitigate, or prevent the disease, public health measures will continue to struggle against the disease. It is imperative that the cure or vaccine should have the potential to reach every individual in the world to defeat COVID-19.
The pharmaceutical sector, specifically biopharmaceuticals, have an opportunity to meet the current demand for a COVID cure. Together with healthcare services, these sectors are in the vanguard, trying to find solutions through
- Repurposing approved drugs
- Convalescent plasma treatment
- Vaccine development – prophylactic as well as therapeutic
The best hope for combating COVID-19 is to develop vaccines – prophylactic and or therapeutic that can immunize or treat the global population. Various vaccine development platforms are being explored by industry and academia alike to find a viable candidate against COVID-19.
Gennova is in a unique position to rapidly provide an end to end solution for vaccine development, and has established itself, over the years, as a preferred research and cGMP manufacturing partner in the area of vaccines. Gennova has had successful collaborations with global academia and institutions in the area of infectious diseases. With a GMP adjuvant manufacturing facility, Gennova is prepared to combat the virus with prophylactic and therapeutic intervention strategies. To increase the chance of success, Gennova is pursuing a two-pronged approach towards combating the virus.
- mRNA based vaccine
- therapeutic neutralizing antibody
